Get the Stockscreener App
2.24
10.34%
0.21
Pre-market:
2.25
0.010
+0.45%
Collplant Biotechnologies Ltd stock is traded at $2.24, with a volume of 86,617.
It is up +10.34% in the last 24 hours and up +52.38% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$2.03
Open:
$2.05
24h Volume:
86,617
Relative Volume:
0.79
Market Cap:
$28.48M
Revenue:
$10.96M
Net Income/Loss:
$-7.02M
P/E Ratio:
-3.50
EPS:
-0.64
Net Cash Flow:
$-3.72M
1W Performance:
+34.94%
1M Performance:
+52.38%
6M Performance:
-44.00%
1Y Performance:
-53.94%
1-Day Range:
$2.04
$2.28
1-Week Range:
$1.5901
$2.28
52-Week Range:
$1.31
$5.45
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
2.24 | 21.11M | 10.96M | -7.02M | -3.72M | -0.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
What analysts say about CollPlant Biotechnologies Ltd. stockFastest-growing stock picks - jammulinksnews.com
What drives CollPlant Biotechnologies Ltd. stock priceRapid wealth creation - Autocar Professional
Is CollPlant Biotechnologies Ltd. a good long term investmentRapidly growing investment returns - Autocar Professional
CollPlant Biotechnologies Ltd. Stock Analysis and ForecastExceptional earning trajectories - jammulinksnews.com
How CollPlant Biotechnologies Ltd. stock performs during market volatilityFree Predictions - Newser
Brown Advisory Inc. Sells 8,265 Shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) - Defense World
Tissue Engineering Market Attracts Investment in Stem Cell - openPR.com
Why CollPlant Biotechnologies Ltd. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser
What makes CollPlant Biotechnologies Ltd. stock price move sharplyTop ROI Selections - Newser
CollPlant names new VP to lead North American commercial operations - Investing.com Australia
COLLPLANT BIOTECHNOLOGIESNEW Earnings Preview: Recent $CLGN Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Collplant Biotechnologies Ltd expected to post a loss of 14 cents a shareEarnings Preview - TradingView
CLGN 6-K: CollPlant Announces New North America Commercial Head | MS SEC FilingForm 424B2 - Stock Titan
CLGN 6-K: CollPlant Announces New North America Commercial Head | CLGN SEC FilingForm 6-K - Stock Titan
CollPlant names new VP to lead North American commercial operations By Investing.com - Investing.com South Africa
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations - Financial Times
CollPlant Accelerates US Expansion: Biotech Veteran to Scale rhCollagen Platform Development - Stock Titan
CollPlant Biotechnologies (NASDAQ:CLGN) Trading Up 2.1% – Should You Buy? - Defense World
CollPlant Biotechnologies shares slide after announces capital raise of $3.6M through registered direct offering - MSN
Is CollPlant Biotechnologies Ltd. overvalued or undervalued? - MarketsMojo
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative - Barchart.com
CollPlant shares rise on expanded partnership with STEMCELL Technologies - MSN
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES - marketscreener.com
CollPlant (CLGN) Expands Partnership with STEMCELL Technologies - GuruFocus
CollPlant Biotechnologies (CLGN) Shares Surge on Expanded STEMCE - GuruFocus
CollPlant's Plant-Based Collagen Advances to Clinical Applications in Major STEMCELL Technologies Deal - Stock Titan
CollPlant secures European patent for collagen products By Investing.com - Investing.com South Africa
CollPlant Biotechnologies Announces European Patent Acceptance Secured for Its Collaboration Multiple as Soft Tissue Fillers and Implants - marketscreener.com
CollPlant secures European patent for collagen products - Investing.com Australia
CollPlant (CLGN) Secures European Patent for Injectable Fillers and Implants | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS - MENAFN.com
CollPlant Biotechnologies Announces $3.6 Million Securities Offering - TipRanks
SEC Form 424B5 filed by CollPlant Biotechnologies Ltd - Quantisnow
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):